Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

van der Touw W, Kang K, Luan Y, Ma G, Mai S, Qin L, et al. Glatiramer Acetate Enhances Myeloid-Derived Suppressor Cell Function via Recognition of Paired Ig-like Receptor B. J Immunol. 2018;201(6):1727-1734.

Roszik J, Ring KL, Wani KM, Lazar AJ, Yemelyanova AV, Soliman PT, et al. Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy. Front Immunol. 2018;9:2102.

Larimer BM, Dubois F, Bloch E, Nesti S, Placzek M, Zadra G, et al. Specific F-FDHT Accumulation in Human Prostate Cancer Xenograft Murine Models Is Facilitated by Prebinding to Sex Hormone-Binding Globulin. J Nucl Med. 2018;59(10):1538-1543.

Mottahedeh J, Haffner MC, Grogan TR, Hashimoto T, Crowell PD, Beltran H, et al. CD38 is methylated in prostate cancer and regulates extracellular NAD. Cancer Metab. 2018;6:13.

Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, H Cook T, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789-796.

Fan J, Wei Q, Koay EJ, Liu Y, Ning B, Bernard PW, et al. Chemoresistance Transmission via Exosome-Mediated EphA2 Transfer in Pancreatic Cancer. Theranostics. 2018;8(21):5986-5994.

Ooki A, Begum A, Marchionni L, VandenBussche CJ, Mao S, Kates M, et al. Arsenic promotes the COX2/PGE2-SOX2 axis to increase the malignant stemness properties of urothelial cells. Int J Cancer. 2018;143(1):113-126.

Natkunam Y, Gratzinger D, Chadburn A, Goodlad JR, Chan JK, Said J, et al. Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal? Blood. 2018;132(18):1871-1878.

Munari E, Zamboni G, Lunardi G, Marchionni L, Marconi M, Sommaggio M, et al. PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections. J Thorac Oncol. 2018;13(8):1113-1120.

Curtis BR, Hsu Y-, Podoltsev N, Lacy J, Curtis S, Samuel MS, et al. Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies. Blood. 2018;131(13):1486-1489.